Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 70, Issue 1, 2008, Pages 75-84

  Wilson, Barnabas ^a   Samanta, Malay Kumar ^a   Santhi, Kumaraswamy ^b   Kumar, Kokilampal Perumal Sampath ^a   Paramakrishnan, Nallupillai ^a   Suresh, Bhojraj ^a  

^a JSS COLLEGE OF PHARMACY   (India)

^b AIMST UNIVERSITY   (Malaysia)

Author keywords

Blood brain barrier; Brain targeting; Nanoparticles; Poly(n butylcyanoacrylate); Tacrine

Indexed keywords

ENBUCRILATE; NANOPARTICLE; NONIONIC SURFACTANT; PHOSPHATE BUFFERED SALINE; POLYMER; POLYSORBATE 80; TACRINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG LIVER LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LUNG; NONHUMAN; RAT; SPLEEN;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CHEMISTRY, PHARMACEUTICAL; CHOLINESTERASE INHIBITORS; DRUG CARRIERS; DRUG STABILITY; ENBUCRILATE; INJECTIONS, INTRAVENOUS; KINETICS; NANOPARTICLES; PARTICLE SIZE; POLYSORBATES; RATS; RATS, WISTAR; SOLUBILITY; SURFACE-ACTIVE AGENTS; TACRINE; TECHNOLOGY, PHARMACEUTICAL;

EID: 50149094833     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.03.009     Document Type: Article

References (71)

1. Tamai I., and Tsuji A. Drug delivery through the blood brain barrier. Adv. Drug Deliv. Rev. 19 (1996) 401-424
2. Misra A., Ganesh S., Shahiwala A., and Shah S.P. Drug delivery to the central nervous system: a review. J. Pharm. Pharmaceut. Sci. 6 (2003) 252-273
3. Vyas S.P., and Khar R.K. Targeted & Controlled Drug Delivery. Novel Carrier Systems (2002), CBS Publishers & Distributors, New Delhi
4. Pardridge W.M. Drug and gene targeting to the brain via blood-brain barrier receptor-mediated transport systems. Int. Cong. Ser. 49 (2005) 49-62
5. Brightman M. Ultrastructure of the brain endothelium. In: Bradbury M.W. (Ed). Physiology and Pharmacology of the Blood-Brain Barrier Handbook of Experimental Pharmcology (1992), Springer, Berlin 1-22
6. Begley D.J. The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J. Pharm. Pharmacol. 48 (1996) 36-46
7. Davson H., and Segal M. Physiology of the CSF and Blood-Brain Barrier (1996), CRC Press, Boca Raton
8. Wolberg H., and Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vasc. Pharmacol. 38 (2002) 323-337
9. Bodor N., Prokai L., Wu W.M., Farag H.H., Jonnalagadda S., Kawamura M., and Simpkins J. A strategy for delivering peptides into the central nervous system by sequential metabolism. Science 257 (1992) 698-1700
10. Devineni D., Klein-Szanto A., and Gallo J.M. Tissue distribution of methotrexate following administration as a solution and as a magnetic microsphere conjugate in rats bearing brain tumors. J. Neurooncol. 24 (1995) 43-152
11. Huwyler J., Wu D., and Pardridge W.M. Brain delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. USA 93 (1996) 4164-14169
12. Kreuter J. Nanoparticle systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47 (2001) 65-81
13. Garcia-Garcia E., Andrieux K., Gil S., and Couvreur P. Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain. Int. J. Pharm. 298 (2005) 274-292
14. Vinogradov S.V., Bronich T.K., and Kabanov A.V. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv. Drug Deliv. Rev. 54 (2002) 135-147
15. Kreuter J., Alyautdin R.N., Kharkevich D.A., and Ivanov A.A. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 674 (1995) 171-174
16. Schroeder U., Sommerfeld P., Ulrich S., and Sabel B.A. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J. Pharm. Sci. 87 (1998) 305-1307
17. Alyautdin R.N., Petrov V.E., Langer K., Berthold A., Kharkevich D.A., and Kreuter J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles. Pharm. Res. 14 (1997) 325-328
18. Alyautdin R.N., Tezikov E.B., Ramge P., Kharkevich D.A., Begley D.J., and Kreuter J. Significant entry of tubocurarine into the brain of rats with polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles: an in situ brain perfusion study. J. Microencpsul. 15 (1998) 67-74
19. Friese A., Seiller E., Quack G., Lorenz B., and Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur. J. Pharm. Biopharm. 49 (2000) 03-109
20. Gulyaev A.E., Gelperina S.E., Skidan I.N., Antropov A.S., Kivman G.Ya., and Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 16 (1999) 1564-1569
21. Kumar V., and Becker R.E. Clinical pharmacology of tetrahydroaminoacridine: a possible therapeutic agent for Alzheimer's disease. Int. J. Clin. Pharmacol. Ther. Toxicol. 27 (1989) 478-485
22. The Merck Index, thirteenth ed. Merck & Co. Inc, NJ, 2001, pp. 1480-1611.
23. Freeman S.E., and Dawson R.M. Tacrine: a pharmacological review. Prog. Neurobiol. 36 (1991) 257-277
24. Sathyan G., Ritschel W.A., and Hussain A.S. Transdermal delivery of Tacrine: I. Identification of a suitable delivery vehicle. Int. J. Pharm. 114 (1995) 75-83
25. Lanctôt K.L., Herrmann N., Yau K.K., Khan L.R., Liu B.A., Loulou M.M., and Einarson T.R. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 169 (2003) 557-564
26. Autuono P., and Beyer J. The burden of dementia. A medical and research perspective. Theor. Med. Bioeth. 20: (1999) 3-13
27. Evans D.A. Estimated prevalence of Alzheimer's disease in the United States. Milbank Q 68 (1990) 267-289
28. Fillit H., Hill J.W., and Fufferman R. Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy. Fam. Med. 34 (2002) 235-528
29. Selkoe D.J. The origins of Alzheimer's disease: A is for amyloid. JAMA 283 (2000) 615-617
30. Spillantini M.G., and Goedert M. The protein pathology in neurodegenerative diseases. Trends Neurosci. 21 (1998) 428-433
31. D.G. Standaert, A.B. Young, Treatment of central nervous system. Degenerative disorders, in: J.G. Hardman, L.E. Limbard (Eds.), Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, p. 560.
32. Green J.D., Baddelay A.D., and Hodges J.R. Analysis of the episodic memory deficit in early Alzheimer's disease: evidence from the doors and people test. Neuropsychologia 34 (1996) 537-551
33. Price B.H., Gurvit H., Weintraub S., Geula C., Leimkuhler E., and Mesulam M. Neuropsychological patterns and language deficits in 20 consecutive cases of autopsy-confirmed Alzheimer's disease. Arch. Neurol. 50 (1993) 931-937
34. Kirk A., and Kertesz A. On drawing impairment in Alzheimer's disease. Arch. Neurol. 48 (1991) 73-77
35. Small G.W., Rabins P.V., Barry P.P., Buckholtz N.S., DeKosky S.T., Ferris S.H., Finkel S.I., Gwyther L.P., Khachaturian Z.S., Lebowitz B.D., McRae T.D., Morris J.C., Oakley F., Schneider L.S., Streim J.E., Sunderland T., Teri L.A., and Tune L.E. Diagnosis and treatment of Alzheimer's disease and related disorders. Consensus statement of the American Association of Geriatric Psychiatry, the Alzheimer's association and the American Geriatric Society. JAMA 278 (1997) 1363-1371
36. http://www.henkel.com. Accessed on January 23, 2004.
37. Kreuter J., Petrov V.E., Kharkevich D.A., and Alyautdin R.N. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J. Control. Release 49 (1997) 81-87
38. Kreuter J., Ramge P., Petrov V., Hamm S., Gelperina S.E., Engelhardt B., Alyautdin R.N., von Briesen H., and Begley D.J. Direct evidence that Polysorbate-80-coated poly(butyl cyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanism requiring prior binding of drugs to the nanoparticles. Pharm. Res. 20 (2003) 409-416
39. Gavini E., Hegge A.B., Rassu G., Sanna V., Testa C., Pirisino G., Karlsen J., and Giunchedi P. Nasal administration of carbamazepine using chitosan microspheres: in vitro/in vivo studies. Int. J. Pharm. 307 (2005) 9-15
40. Hejazi R., and Amiji M. Stomach-specific anti-H. pylori therapy Part III: effect of chitosan microspheres crosslinking on the gastric residence and local tetracycline concentrations in fasted gerbils. Int. J. Pharm. 272 (2004) 99-108
41. Marchal-Heussler L., Maincent P., Hoffman M., Spittler J., and Couvreur P. Antiglaucomatous activity of betaxolol chlorhydrate sorbed onto different isobutyl cyanoacrylate nanoparticles preparations. Int. J. Pharm. 58 (1990) 115-122
42. Costa P., and Lobo J.M.S. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13 (2001) 123-133
43. Zhang Z., Liao G., Nagai T., and Hou S. Mitoxantrone polybutyl cyanoacrylate nanoparticles as an anti-neoplastic targeting drug delivery system. Int. J. Pharm. 139 (1996) 1-8
44. Löbenberg R., Araujo L., von Brisen H., Rodgers E., and Kreuter J. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J. Control. Release 50 (1998) 21-30
45. Telting-Diaz M., and Lunte C.E. Distribution of tacrine across the blood-brain barrier in awake, freely moving rats using in vivo microdialysis sampling. Pharm. Res. 10 (1993) 44-48
46. Couvreur P., Kante B., Roland M., Guiot P., Baudini P., and Speiser P. Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J. Pharm. Pharmacol. 31 (1979) 331-332
47. Couvreur P., Roland M., and Speiser P. Procedé de preparation de particules submicroscopiques, particules ainsi obtenues et compositions pharmaceutiques ques les contenant. European Patent No. 0064967 (1985)
48. Behan N., Birkinshaw C., and Clarke N. Poly(n-butylcyanoacrylate) nanoparticles: a mechanistic study of polymerization and particle formation. Biomaterials 22 (2001) 1335-1344
49. Kreuter J. Nanoparticles. In: Kreuter (Ed). Colloidal Drug Delivery System (1994), Marcel Dekker, New York 219-342
50. Verdun C., Couvreur P., Vranckx H., Lenaerts V., and Roland M. Development of a nanoparticles controlled-release formulation for human use. J. Control. Release 3 (1986) 205-210
51. Allemann E., Gurny R., and Deolker E. Drug loaded nanoparticles: preparation methods and drug targeting issues. Eur. J. Pharm. Biopharm. 39 (1993) 73-191
52. Banerjee T., Mitra S., Singh A.K., Sharma R.K., and Maitra A. Preparation and biodistribution of ultrafine chitosan nanoparticles. Int. J. Pharm. 243 (2002) 93-105
53. Wisse E., and Leeuw A.M. Structural elements determining transport and exchange process in the liver. In: Daviss S.S., Illum L., McVie J.G., and Tomlinson E. (Eds). Microspheres And Drug Therapy, Pharmaceutical, Immunological and Medical Aspects (1984), Elsevier, Amsterdam 1-23
54. Seijo B., Fattal E., Roblot-Treupel L., and Couvreur P. Design of nanoparticles of less than 50 nm diameter: preparation, characterization and drug loading. Int. J. Pharm. 62 (1990) 1-7
55. Hans M.L., and Lowman A.M. Biodegradable nanoparticles for drug delivery and targeting. Curr. Opin. Solid State Mater. Sci. 6 (2002) 319-327
56. Muller R.H., Jacobs C., and Kayser O. Nanosuspensions as particulate drug formulations in therapy, rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47 (2001) 3-19
57. Vila A., Sánchez A., Tobío M., Calvo P., and Alonso M.J. Design of biodegradable particles for protein delivery. J. Control. Release 78 (2002) 15-24
58. Reddy L.H., and Murthy R.S.R. Pharmacokinetics and biodistribution studies of doxorubicin loaded poly(butylcyanoacrylate) nanoparticles synthesized by two different techniques. Biomed. Papers 148 (2004) 161-166
59. Agnihotri S.A., Mallikarjuna N.N., and Aminabhavi T.M. Recent advances on chitosan-based micro-and nanoparticles in drug delivery. J. Control. Release 100 (2004) 5-28
60. Fawaz F., Guyot M., Lagueny A.M., and Devissaguet J.Ph. Ciprofloxacin-loaded poly(isobutylcyanoacrylate) nanoparticles: preparation and characterization. Int. J. Pharm. 154 (1997) 191-203
61. Wu Y., Yang W., Wang C., Hu J., and Fu S. Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate. Int. J. Pharm. 295 (2005) 235-245
62. Genta I., Costantini M., Asti A., Conti B., and Montanari L. Influence of glutaraldehyde on drug release and mucoadhesive properties of chitosan microspheres. Carbohyd. Polym. 36 (1998) 81-88
63. Bayomi M.A., Al-Suwaych S.A., El-Helw A.M., and Mesnad A.F. Preparation of casein chitosan microspheres containing diltiazem hydrochloride by an aqueous coacervation technique. Pharm. Acta Helv. 73 (1998) 187-192
64. Grislain L., Couvreur P., Lenaerts M., Roland M., Deprez-decampeneere D., and Speiser P. Pharmacokinetics and distribution of a biodegradable drug-carrier. Int. J. Pharm. 15 (1983) 335-345
65. Douglas S.J., Illum L., Davis S.S., and Kreuter J. Particle size and size distribution of poly(butyl-2-cyanoacrylate) nanoparticles. J. Col. Interf. Sci. 101 (1984) 149-158
66. Chiannilkulchai N., Ammoury N., Caillou B., Devissageut J., and Couvreur P. Hepatic tissue distribution of doxorubicin loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastases-bearing mice. Cancer Chemother. Pharmacol. 26 (1990) 122-126
67. 3H-labelled dalargin bound to poly(butylcyanoacrylate) nanoparticles after i.v. injections to mice. Life Sci. 66 (2000) 495-502
68. Tröster S.D., Müller U., and Kreuter J. Modification of the body distribution of poly(methylmethacrylate) nanoparticles in rats by coating with surfactants. Int. J. Pharm. 61 (1990) 85-100
69. Borchard G., Audus K.L., Shi F., and Kreuter J. Uptake of surfactant-coated poly(methylmethacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers. Int. J. Pharm. 110 (1994) 29-35
70. Sun W., Xie C., Wang H., and Hu Y. Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials 25 (2004) 3065-3071
71. Kreuter J., Shamenkov D., Petrov V., Ramge P., Cychutek K., Koch-Brandt C., and Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target. 10 (2002) 317-325